Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. [PDF]
J Am Heart Assoc, 2018 Background Our objective was to determine patterns of antihypertensive agent use by stage of chronic kidney disease (CKD) and to evaluate the association between different classes of antihypertensive agents with nonrenal outcomes, especially in advanced ...
Ku E +4 more
europepmc +4 more sources
Antihypertensive Agents and Incident Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Observational Studies [PDF]
The journal of prevention of Alzheimer's disease, 2022 Background Hypertension is a recognized risk factor for dementia. However, evidence for using antihypertensive agents to reduce the risk of Alzheimer’s disease in people with hypertension is inconclusive. Objective To examine the association between
Adesuyan, M +7 more
core +2 more sources
Systolic Blood Pressure Variability When Transitioning From Intravenous to Enteral Antihypertensive Agents in Patients With Hemorrhagic Strokes [PDF]
Frontiers in Neurology, 2022 Background/ObjectiveSystolic blood pressure variability (SBPV) in patients with intracranial hemorrhage (ICH) and subarachnoid hemorrhage (SAH) is associated with an increased risk of acute kidney injury (AKI) and mortality. SBPV is a strong predictor of
Abdulrahman I. Alshaya +18 more
doaj +2 more sources
Propranolol as an antihypertensive agent in children. [PDF]
Archives of Disease in Childhood, 1978 The antihypertensive effect of oral propranolol was studied in 9 children with hypertension. After treatment with propranolol, systolic blood pressure fell by an average of 26 mmHg (P less than 0.01). Diastolic pressure decreased by 20 mmHg on average (P less than 0.01). The mean propranolol dose was 2.5 mg/kg per day. Side effects included bradycardia
William R. Griswold +4 more
openalex +5 more sources
Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19. [PDF]
Cardiovasc Drugs Ther, 2022 Chouchana L +12 more
europepmc +2 more sources
Risk of Parkinson's Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies. [PDF]
J Neurodegener Dis, 2016 Background. Antihypertensive agents have been shown to inhibit oxidative stress and inflammatory response and thus neuroprotection in Parkinson's disease (PD).
Mullapudi A +3 more
europepmc +2 more sources
Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis. [PDF]
Br J Clin Pharmacol, 2014 AIMS In response to safety concerns from two large randomized controlled trials, we investigated whether the use of telmisartan, an angiotensin receptor blocker (ARB), ARBs as a class and angiotensin-converting enzyme inhibitors (ACEIs) increase the risk
Dial S +4 more
europepmc +2 more sources
Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study. [PDF]
PLoS One, 2014 Background and Purpose Hypertension has been associated with Parkinson's disease (PD), but data on antihypertensive drugs and PD are inconclusive. We aim to evaluate antihypertensive drugs for an association with PD in hypertensive patients.
Lee YC +5 more
europepmc +2 more sources
Cognition and drug adherence to oral hypoglycemic and antihypertensive agents in older adults [PDF]
Patient Preference and Adherence, 2019 Hamzah Bakouni,1,2 Lia Gentil,3 Helen-Maria Vasiliadis1–2,41Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada; 2Centre de recherche Charles-Le Moyne – Saguenay–Lac-Saint-Jean sur les ...
Bakouni H, Gentil L, Vasiliadis HM
doaj +2 more sources
Antihypertensive agents: a long way to safe drug prescribing in children. [PDF]
Pediatr Nephrol, 2020 Siddiqi N, Shatat IF.
europepmc +2 more sources